New Delhi, Oct. 14 -- Swiss drugmaker Roche has moved the Supreme Court, seeking to restrain Natco Pharma from selling the generic version of its life-saving spinal muscular atrophy (SMA) drug Risdiplam in India.

Roche approached the apex court after the Delhi High Court division bench on 9 October refused to bar Natco Pharma from selling the generic version, upholding a March single-judge order that had earlier denied Roche an injunction.

The plea for urgent listing was mentioned on Tuesday by Roche's counsel before a bench led by Chief Justice B.R. Gavai, which agreed to hear the matter on Thursday or Friday.

Sold under the brand name Evrysdi, Risdiplam is used to treat spinal muscular atrophy (SMA), a rare genetic disorder that caus...